RA leads $45m round for PepGen

Oxford Sciences Innovation, The University of Oxford and CureDuchenne Ventures also participated in the round.

PepGen will use the funding to advance its cell-penetrating peptides conjugated to phosphorodiamidate morpholino oligomers (PPMO), designed to correct genetic defects in diseases with high unmet medical need.

Joshua Resnick, managing director at RA Capital Management, has become a member of the PepGen board of directors.

PepGen's new corporate headquarters will be in Boston, and its research hub will continue to be in the UK.

Previous funding
With a seed investment of £4.5m from OSI, PepGen was spun out in 2018 to commercialise its cell-penetrating peptide platform. The company was additionally supported by a £1.6m grant from Innovate UK, the UK's innovation agency.

Company
PepGen is an Oxford-headquartered biotechnology company. In addition to its flagship treatment for Duchenne muscular dystrophy, PepGen has a pipeline of drugs targeting rare neuromuscular and neurological diseases, with a particular focus on those with severe cardiac manifestations, as well as primary cardiac conditions.

People
RA Capital Management – Ramin Farzaneh-Far (venture partner); Joshua Resnick (managing director).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• UK / Ireland
• Healthcare
• United Kingdom
• healthcare